Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
AssigneeHealth Research, Inc.
InventorBen K. Seon
Life of this patent
Estimating the term…
Abstract
A monoclonal antibody, or fragments thereof, having binding specificity for both endoglin expressed on human vascular endothelial cells and on murine endothelial cells. Antiangiogenic therapy in mammals can be effected by administering to the mammalian host a therapeutically effective amount of an anti-endoglin monoclonal antibody, or fragment thereof, either unconjugated or conjugated to at least one angiogenesis inhibitor or antitumor agent. The composition is useful for treating tumor and angiogenesis-associated diseases.
Claims25
A composition for antiangiogenic therapeutic treatment of an angiogenesis-associated disease comprising tumor angiogenesis or other angiogenesis-associated disease in a mammalian host, wherein the composition comprises a monoclonal antibody, or antigen binding fragments thereof, having binding specificity for crossreactive epitopes shared by endoglin expressed on human vascular endothelial cells and endoglin expressed on murine vascular endothelial cells.
Dependencies are inferred from the claim text.